CD19 and acute myeloid leukemia: These demonstrated that CD19 CAR-T cell therapy was effective in R/R t(8;21) AML patients with aberrant CD19 expression, which might further expand the application of CD19 CAR-T cell therapy, beyond B-cell malignancies.